Skip to main content

ABL Acquires Assets of Evivar Medical

NEW YORK (GenomeWeb News) – Advanced Biological Laboratories, a Luxembourg-based developer of informatics tools for personalized medicine, today announced that it has acquired all of the assets of Evivar Medical for an undisclosed amount.

The acquisition includes Melbourne, Australia-based Evivar's hepatitis B and C virus web-based decision support tools for clinicians and associated viral genome analysis systems SeqHepB and SeqHepC, its intellectual property portfolio, and all related commercial arrangements and operations. The SeqHepB and SeqHepC systems are used for hepatitis B and C therapy management and can be used to identify mutations present in the infected persons, including predicting resistance levels to commercially available drugs, the firms said.

"Our acquisition of Evivar Medical assets will add value and allows ABL to further expand its Virology portfolio from HIV to include Hepatitis disease management," ABL President and CEO Chalom Sayada.

The Evivar tools will complement ABL's existing data tools including its TherapyEdge, ViroScore, and DeepChek products.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.